Active Biotech AB (DE:BTPC)
FRANKFURT:BTPC
BTPC Stock Chart & Stats
€0.01
<€0.01(14.29%)
At close: 4:00 PM EST
€0.01
<€0.01(14.29%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.02
Previous CloseN/A
Volume20.00K
Average Volume (3M)7.13K
Market Cap
€10.52M
Enterprise Value-€8.55M
Total Cash (Recent Filing)€65.10M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-6.69
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding2,636,067,100
10 Day Avg. Volume2,383
30 Day Avg. Volume7,129
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.11
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low debt and a move to zero reported debt in 2025 materially reduce fixed financing costs and preserve strategic optionality. For a development-stage biotech, low leverage supports flexibility to pursue partnerships, tolerate near-term losses, and avoid interest-driven cash drains while advancing R&D programs.
Partnering/licensing Business ModelA focus on out-licensing and collaborations aligns the company with a capital-efficient commercialization path: limited manufacturing and commercial spend, milestone-driven upside, and royalty streams if assets succeed. This model fits a small R&D-focused company and can sustainably monetize pipeline assets without becoming a commercial operator.
Improving Cash-burn And Asset BaseNarrowing operating losses alongside a notable increase in total assets suggests progress toward financial stabilization: reduced cash burn eases near-term financing needs, while a larger asset base strengthens balance-sheet capacity to support ongoing R&D or to underpin partnering negotiations and milestone-based funding.
Bears Say
No Product RevenueZero reported revenue for multiple consecutive years means the company lacks recurring product sales and is entirely reliant on partnerships, milestones or financings. This creates a binary outcome profile where value realization depends on successful licensing deals or partner-driven development events rather than steady cash generation.
Sustained Negative Operating Cash FlowMaterial negative operating cash flow, even after improvement, implies ongoing cash burn and frequent dependence on external financing or milestone receipts. Continued negative OCF constrains the company's ability to self-fund clinical programs, raises dilution and refinancing risk, and limits strategic flexibility absent partner funding.
Persistent Net LossesConsistent multi-year net losses reflect a lack of profitability and negative returns for shareholders. Persistent losses necessitate further capital raises or asset sales, can dilute existing holders, and indicate that R&D investment has yet to produce revenue-generating assets or partner-triggered milestones to offset the cost base.
Active Biotech AB News
BTPC FAQ
What was Active Biotech AB’s price range in the past 12 months?
Active Biotech AB lowest stock price was <€0.01 and its highest was €0.02 in the past 12 months.
What is Active Biotech AB’s market cap?
Active Biotech AB’s market cap is €10.52M.
When is Active Biotech AB’s upcoming earnings report date?
Active Biotech AB’s upcoming earnings report date is May 07, 2026 which is in 38 days.
How were Active Biotech AB’s earnings last quarter?
Active Biotech AB released its earnings results on Feb 12, 2026. The company reported >-€0.001 earnings per share for the quarter, missing the consensus estimate of N/A by >-€0.001.
Is Active Biotech AB overvalued?
According to Wall Street analysts Active Biotech AB’s price is currently Overvalued.
Does Active Biotech AB pay dividends?
Active Biotech AB does not currently pay dividends.
What is Active Biotech AB’s EPS estimate?
Active Biotech AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Active Biotech AB have?
Active Biotech AB has 2,636,067,100 shares outstanding.
What happened to Active Biotech AB’s price movement after its last earnings report?
Active Biotech AB reported an EPS of >-€0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -9.091%.
Which hedge fund is a major shareholder of Active Biotech AB?
Currently, no hedge funds are holding shares in DE:BTPC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Active Biotech AB
Active Biotech AB (publ), a biotechnology company, develops pharmaceutical products the treatment of oncology and immunology diseases in Sweden. It is developing Tasquinimod, a small molecule immuno-modulator, which is in Phase Ib/IIa clinical trial to treat multiple myeloma; Laquinimod, an immunomodulator that is in phase I clinical trial for the treatment of inflammatory eye disorders, including uveitis; and Naptumomab, an anti-cancer immunotherapy, which is in phase Ib/II clinical trial to treat patients with advanced solid tumors. The company has a licensing agreement with NeoTX Therapeutics Ltd. for the development and commercialization of Naptumomab for cancer immunotherapy. Active Biotech AB (publ) was incorporated in 1983 and is headquartered in Lund, Sweden.
Technical Analysis
Medivir AB
―
Isofol Medical AB
―
Xintela AB
―
Elicera Therapeutics AB
―
IRLAB Therapeutics AB Class A
―